evipedia.ai
← Back

Young Plasma Transfusion for Health & Longevity

Evidence Review created on 08/15/2026 using AI4L / Opus 5

Also known as: Young Plasma Infusion, Young Blood Transfusion, Young Fresh Frozen Plasma, Heterochronic Plasma Transfer, Young Plasma Exchange

Motivation

Young plasma transfusion means giving an older adult the liquid, cell-free portion of blood donated by a young, healthy person. Interest in it grew out of animal work in which old mice and rats sharing circulation with young ones showed better muscle repair, healthier livers and improved memory. The underlying idea is that blood carries signals that change with age.

Transfusing plasma is not new. Hospitals have used it for decades to replace clotting proteins and treat bleeding. What is new is offering it to people who are not ill. Private clinics began selling infusions to healthy adults for thousands of dollars a session, and the United States drug regulator has publicly warned that no proven benefit exists for such use and that the infusions carry real risks.

This review examines what the human evidence shows about giving plasma from young donors to older adults: how it is thought to work, what the trials have measured and what they have not, what the procedure involves, what can go wrong, and how far the findings on each side of the debate actually reach.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews of young plasma transfusion from expert practitioners, longevity publications and clinical scientists.

  • Modern Vampirism: “Young Blood” Transfusions - Birkenbach & Attia

    Dissects the Alzheimer’s plasma trial’s within-group statistics and partial unblinding, explaining why its apparent functional gains do not establish efficacy, and why isolating individual blood factors may prove more tractable than whole plasma.

  • Restore Youthfulness & Vitality to the Aging Brain & Body – Dr. Tony Wyss-Coray - Huberman

    Two-hour interview with the Stanford neurologist whose laboratory generated much of the young-blood literature, covering which circulating factors matter, why banking one’s own plasma is impractical, and organ-specific aging clocks.

  • Two new interventions that can reverse epigenetic age – Dr. Morgan Levine - Patrick

    Extended exchange tracing parabiosis through to plasma exchange, weighing whether youthful factors or accumulated aged factors drive the effect, and asking how long any benefit survives once treatment stops.

  • How Plasma Exchange Affects Aging in a Human Trial - Conway

    Detailed lay read-out of the placebo-controlled plasma exchange trial in adults over fifty, including clock-by-clock results, the loss of effect at later timepoints, and the missing immunoglobulin-only comparison arm.

  • The Prospect of Human Age Reversal - Faloon

    Advocacy-side account by a supplement-company founder who co-funded rat young-plasma work; useful for the strongest case made for the approach and the animal results proponents cite.

Note for the reader: chriskresser.com is not represented above; the only material found there is a brief exchange on parabiosis and plasmapheresis inside a wide-ranging longevity podcast episode, not a high-level treatment of this intervention. The Life Extension item is by the founder of a supplement retailer that co-funded the animal research it describes, and is included as advocacy.

Grokipedia

  • Young blood transfusion

    Consolidates the parabiosis literature (surgically joining two animals’ circulations), the commercial clinic history and the regulatory response into one reference entry, useful for orientation before reading the primary trials.

Examine

No Examine article exists for young plasma transfusion. Examine covers dietary supplements and nutrition interventions, and does not cover blood products or physician-administered biologics, which is the category this intervention falls into.

ConsumerLab

No ConsumerLab article exists for young plasma transfusion. ConsumerLab tests commercially sold supplements and consumer health products, and does not cover blood products or physician-administered biologics such as donor plasma.

Systematic Reviews

This section lists the systematic reviews and meta-analyses bearing on young plasma transfusion, covering both the claimed cognitive and functional benefits and the principal procedural risks, since no systematic review addresses young plasma in healthy adults specifically.

Mechanism of Action

Plasma is a mixture of thousands of proteins, lipids, metabolites and extracellular vesicles whose composition shifts measurably across the lifespan. Two competing mechanistic accounts exist, and the field has not settled between them.

The “add-back” model holds that young plasma supplies pro-regenerative signals that decline with age. Candidate factors include growth differentiation factor 11 (GDF11, a protein in the transforming growth factor beta family that regulates tissue growth), tissue inhibitor of metalloproteinases 2 (TIMP2, a brake on tissue remodeling), klotho and oxytocin. In aged mice, young circulation restored stem-cell activation through Notch signaling (a cell-to-cell communication system controlling stem-cell fate) (Conboy et al., 2005); young plasma improved memory via CREB (a gene-switching protein required for forming new memories) (Villeda et al., 2014).

The “dilution” model holds the opposite: benefit comes from removing accumulated pro-aging factors such as CCL11/eotaxin (an immune signaling protein that suppresses new neuron formation), transforming growth factor beta 1 and beta-2 microglobulin. Replacing half of an old mouse’s plasma with saline and albumin, containing no young plasma at all, reproduced the muscle, liver and brain benefits (Mehdipour et al., 2020).

Pharmacologically, plasma has no single half-life. Infused albumin persists roughly 19 days and immunoglobulin G roughly 21 days, while most signaling proteins clear within hours to days. Plasma proteins distribute across the intravascular and interstitial compartments and are catabolized by endothelial and reticuloendothelial cells, not by hepatic cytochrome P450 enzymes (the liver’s main drug-metabolizing enzyme family). No depot forms, so any durable effect must be indirect.

Historical Context & Evolution

Plasma transfusion entered medicine as a wartime volume expander and clotting-factor replacement, and remains licensed for bleeding, coagulation-factor deficiency and plasma exchange in specific diseases. Its use as a longevity intervention traces to a separate line of work: parabiosis, the surgical joining of two animals so they share a circulation, described by Paul Bert in 1864.

In the 1950s Clive McCay’s group at Cornell joined old and young rats and reported that the older partner’s cartilage, bone and body weight shifted toward the younger animal’s profile (McCay et al., 1957). The technique then lay largely dormant for four decades, partly because of surgical mortality and partly because the field lacked molecular tools to identify what was being exchanged.

It returned in 2005, when Conboy et al. showed that aged satellite cells (muscle stem cells) and liver progenitors regained proliferative capacity in young circulation, restoring Notch signaling. Cell-free plasma injections reproduced parts of the effect, moving attention from cells to soluble factors.

Opinion has since moved in both directions. The 2013 identification of GDF11 as a rejuvenating factor (Loffredo et al., 2013) was followed by reports that the original assays could not distinguish GDF11 from the closely related protein myostatin, and that GDF11 levels may rise rather than fall with age (Egerman et al., 2015); those reports were themselves contested on assay grounds, and the question is unresolved rather than closed. Meanwhile, commercial clinics moved ahead of the evidence, prompting the 2019 regulatory warning that reframed the field’s public standing.

Expected Benefits

Benefits below are framed for a health- and longevity-oriented adult considering this intervention electively, not for patients receiving plasma for a licensed medical indication. Every human outcome to date comes from small trials, most in disease populations, and several were sponsored by companies that sell plasma or plasma-derived products.

Medium 🟩 🟩

Reduction in Epigenetic Age Estimates ⚠️ Conflicted

Epigenetic clocks estimate biological age from chemical marks on DNA. In a placebo-controlled trial of 42 adults over 50 run by Global Apheresis and Circulate Health, commercial providers of the procedure, plasma exchange combined with intravenous immunoglobulin (pooled donor antibodies) lowered a composite clock score, with fifteen clocks showing rejuvenation versus placebo (Fuentealba et al., 2025). A randomized crossover trial of plasmapheresis (drawing off plasma and returning the blood cells) without replacement fluid found the opposite direction (Borsky et al., 2025). Neither used young-donor plasma as replacement.

Magnitude: Composite biological age fell 2.61 years with twice-weekly exchange plus immunoglobulin and 1.32 years with monthly exchange at two months, with no benefit at the later timepoint; the opposing trial reported acceleration on three clocks.

Low 🟩

Dampened Inflammatory Response to Surgical Tissue Injury

In 38 older patients undergoing joint replacement, a young-donor plasma fraction shifted immune signaling toward an anti-inflammatory pattern, reducing MAPK (a stress-signaling cascade) and JAK-STAT (a cytokine-signaling pathway) activity (Gaudilliere et al., 2025). Endpoints were laboratory measures; no recovery benefit was shown. Alkahest, owned by plasma manufacturer Grifols, supplied it.

Magnitude: Regression models separated treated from placebo patients with an area under the curve (a 0–1 measure of how well a model discriminates) of 0.796 for the protein profile and 0.904 for the immune-cell response.

Preserved Cognitive and Functional Scores in Alzheimer’s Disease ⚠️ Conflicted

Plasma exchange with albumin slowed decline on daily-living and cognitive scales in a 347-patient trial run by Grifols (Boada et al., 2020), and plasma fractions held scores stable in uncontrolled cohorts (Hannestad et al., 2020). Pooled across trials, no cognitive benefit survived (Fei et al., 2022).

Magnitude: Decline on the daily-living scale was 52% smaller than placebo over 14 months and 61% smaller in the moderate subgroup; the pooled analysis found no significant difference.

Improved Verbal Fluency in Parkinson’s Disease

Fifteen people with Parkinson’s disease received eight infusions of young fresh frozen plasma in an open-label study with no placebo arm (Parker et al., 2020). Phonemic fluency and a stigma subscore improved and held four weeks later. Elevated tumor necrosis factor alpha (an inflammatory signaling protein) fell.

Magnitude: Direction was favorable and improvements persisted four weeks after the final infusion, but the report gives no effect size, and without a control arm no outcome figure can be attributed to the plasma itself.

Improved Kidney-Function and Mortality-Risk Biomarkers After Umbilical Cord Plasma

Eighteen adults averaging 74 years received ten weekly intramuscular injections of umbilical cord plasma concentrate in an uncontrolled safety study run by the commercial provider Betterhumans (Clement et al., 2022). Over twenty clinical biomarkers moved favorably, though with no control group, ordinary fluctuation cannot be excluded.

Magnitude: The mortality-risk clock GrimAge fell an average of 0.82 years; creatinine fell and estimated glomerular filtration rate (a calculated measure of kidney filtering capacity) rose significantly.

Speculative 🟨

Extension of Healthy Lifespan

Old rats given young plasma outlived untreated controls, and prolonged parabiosis lowered biological age in old mice. No human study has measured survival, so the basis is animal data only.

Restoration of Multi-Tissue Regenerative Capacity

Young circulation restored muscle, liver, bone and hippocampal regeneration in rodents. No human trial has measured tissue regeneration, and the closest human readouts are protein signatures, so this remains mechanistic extrapolation.

Benefit-Modifying Factors

  • APOE ε4 carrier status: APOE encodes a lipid-transport protein; the ε4 variant raises Alzheimer’s risk. The Alzheimer’s plasma exchange trial found larger benefit in more impaired patients (Boada et al., 2020), but no analysis has reported whether ε4 carriers respond differently.

  • Baseline inflammatory and immune biomarkers: People with poorer baseline health, indexed by monocyte and platelet profiles, were the stronger responders in the plasma exchange trial (Fuentealba et al., 2025). Healthy, low-inflammation adults showed little measurable change, which is directly relevant to elective use.

  • Baseline epigenetic age acceleration: Where the outcome measured is a clock score, those starting with accelerated clocks have more room to move. Trials showed meaningful baseline clock differences between groups, which confounds interpretation of who benefits.

  • Sex-based differences: No trial has reported sex-stratified efficacy. Donor sex matters for safety rather than benefit, and recipient sex differences in plasma protein composition across the lifespan have not been translated into differential response data.

  • Pre-existing conditions: Neurodegenerative disease, chronic kidney disease and chronic inflammatory conditions alter the plasma proteome (the full set of blood proteins). Every positive human signal to date comes from a disease population, so extrapolation to a healthy adult is not evidence-based.

  • Age at the older end of the target range: Trials enrolled adults from 50 to 90 years. Preclinical work suggests the gap between donor and recipient age drives the effect, implying older recipients would respond more, but this has not been tested in humans.

Potential Risks & Side Effects

Risks below are framed for a healthy adult electing this procedure, for whom every adverse event is incurred without an offsetting treatment indication. Per-unit reaction rates come from hospital transfusion populations, and elective protocols using large volumes over repeated sessions accumulate exposure faster than a single therapeutic transfusion.

High 🟥 🟥 🟥

Allergic and Anaphylactic Reactions

Plasma proteins can trigger hypersensitivity ranging from urticaria (hives) to airway obstruction. Risk is highest in people with immunoglobulin A deficiency, who can form antibodies against donor immunoglobulin A. The US Food and Drug Administration (FDA) named allergic reactions among the principal hazards of young donor plasma, and one participant in the Alzheimer’s young-plasma trial withdrew because of urticaria (Sha et al., 2019).

Magnitude: Pooled rates are about 92 allergic reactions and 0.8 anaphylactic reactions per 100,000 plasma units transfused (Saadah et al., 2017).

Donor antibodies against recipient white cells trigger leakage in the lung’s small vessels, causing low blood oxygen within six hours of transfusion. It is a leading cause of transfusion-related death. The two meta-analyses disagree by roughly tenfold because passive hospital reporting misses cases that prospective active surveillance captures; the discrepancy reflects detection method, not a genuine difference in biology.

Magnitude: 1.8 cases per 100,000 plasma units under passive reporting (Saadah et al., 2017) versus 3.19 per 10,000 plasma components under active surveillance (White et al., 2024).

Medium 🟥 🟥

Transfusion-Associated Circulatory Overload

Infusing large plasma volumes expands blood volume faster than the heart and kidneys can compensate, producing breathlessness, raised blood pressure and fluid in the lungs. The FDA singled this out for people with pre-existing heart disease, noting that elective protocols use volumes not guided by controlled dosing data. Commercial protocols delivering one to two liters per session are well above a standard therapeutic unit.

Magnitude: About 6 cases per 100,000 plasma units transfused, rising with larger infused volumes and in people with heart failure or reduced kidney function (Saadah et al., 2017).

Febrile Non-Hemolytic Transfusion Reactions

Cytokines (immune signaling proteins) accumulated during storage and recipient antibodies against donor white-cell antigens cause fever, chills and shivering during or shortly after infusion, without any red-cell destruction. The reaction is self-limiting and rarely dangerous, but it is the most common reason an elective infusion is interrupted, and it is indistinguishable at onset from the early phase of a hemolytic or septic reaction.

Magnitude: About 12 reactions per 100,000 plasma units, with roughly 15 fewer per 100,000 when methylene-blue-treated plasma is used instead of standard fresh frozen plasma (Saadah et al., 2017).

Citrate-Induced Hypocalcemia During Apheresis

Where plasma is delivered by exchange rather than simple infusion, citrate anticoagulant in the apheresis circuit (the machine loop the blood is routed through) binds ionized calcium, causing hypocalcemia (low blood calcium): tingling around the mouth, paresthesia (pins and needles), and rarely tetany (sustained muscle spasm) or irregular heartbeat. Calcium fell measurably during the large Alzheimer’s exchange program, and this is the single most common apheresis side effect (Grifols et al., 2023).

Magnitude: Blood calcium declined consistently after full-volume exchange while remaining within the reference range; the trial report gives no incidence figure for symptomatic hypocalcemia.

Depletion of Immunoglobulins and Clotting Factors by Plasma Exchange

Exchanging plasma for albumin removes antibodies and coagulation proteins along with the intended targets, transiently raising infection and bleeding risk. In the Alzheimer’s program, low gamma globulin persisted between sessions rather than fully recovering, meaning repeated cycles produce a cumulative deficit that a single-session safety report would not detect.

Magnitude: Fibrinogen, total protein, gamma globulin and immunoglobulin G transiently fell below the reference range after weekly full-volume exchange, and low gamma globulin at 7.2 g/L persisted before subsequent sessions (Grifols et al., 2023).

Exchange requires high-flow venous access. Where peripheral veins are inadequate, a central venous catheter is placed, adding collapsed lung, clot formation and catheter infection to the hazard list. Procedure-related events were far more frequent with active treatment than with sham, and central access roughly doubled them relative to peripheral access (Boada et al., 2023).

Magnitude: At least one adverse event occurred in 16.9% of 1,283 full-volume exchanges and 12.5% of 2,203 low-volume exchanges versus 0.7% of 1,223 sham procedures; 20.1% with central access versus 13.1% with peripheral access.

Residual Transfusion-Transmitted Infection

Donor screening and nucleic acid testing have reduced but not eliminated viral transmission, because infections acquired in the window before antibodies appear escape detection. The FDA listed infectious risk first among the hazards of young donor plasma. Elective repeated exposure multiplies a per-donation risk that a single medically indicated transfusion incurs once.

Magnitude: Estimated residual risk per donation in United States donors is about 1 in 1.6 million for HIV, 1 in 2.0 million for hepatitis C and 1 in 1.0 million for hepatitis B (Steele et al., 2021).

Low 🟥

Immune Sensitization and Red-Cell Destruction from Donor Antibodies

Plasma carries donor antibodies against blood-group antigens, which can destroy recipient red cells if ABO-mismatched plasma is given. Repeated exposure to donor tissue antigens can also produce alloantibodies (antibodies against another person’s tissue) complicating later transfusion or transplantation (Petrányi et al., 1997). Correct matching makes this rare.

Magnitude: Not quantified in available studies. No trial of young plasma transfusion has measured antibody formation or red-cell destruction in elective recipients, so only the general transfusion literature describes the mechanism.

Speculative 🟨

Delivery of Growth-Promoting Factors

Young plasma is enriched in growth and vessel-forming factors, the same signals that support tumor growth. No study has measured cancer incidence after exposure; the concern is mechanistic, and trials excluded recent cancer.

Unknown Consequences of Repeated Long-Term Exposure

No study has followed elective recipients beyond months. Concerns include emerging or unscreened pathogens, prion transmission, and cumulative immune sensitization. The basis is transfusion history, not observation in young plasma recipients.

Risk-Modifying Factors

  • Immunoglobulin A deficiency: The commonest primary immune deficiency, often silent. Affected people may carry anti-immunoglobulin A antibodies and face markedly elevated anaphylaxis risk from plasma. Trials of young plasma excluded such individuals by screening, and elective clinics may not.

  • Baseline fibrinogen, immunoglobulin G and calcium: Low starting values leave less reserve before exchange pushes them below the reference range, converting a transient dip into clinically relevant bleeding, infection susceptibility or symptomatic hypocalcemia.

  • Sex of donor and recipient: Plasma from previously pregnant female donors carries anti-leukocyte antibodies; male-only plasma reduced lung-injury rates by about 0.74 cases per 100,000 units (Saadah et al., 2017). Recipient-sex differences in reaction rates have not been established.

  • Pre-existing cardiac and renal disease: Heart failure and reduced glomerular filtration limit the ability to handle a large infused volume, converting a routine infusion into circulatory overload. The FDA named cardiac disease specifically in its warning.

  • Age at the older end of the target range: Older recipients have less cardiac and renal reserve, more coexisting illness, and thinner peripheral veins, raising both circulatory-overload risk and the likelihood of needing central venous access.

  • Prior transfusion or pregnancy history: Previous exposure to foreign leukocyte antigens raises the probability of pre-existing alloantibodies, increasing febrile reaction risk and complicating cross-matching for any future transfusion or transplant.

Key Interactions & Contraindications

  • Vitamin K antagonists — blood thinners (warfarin, acenocoumarol): Caution. Donor plasma supplies clotting factors, transiently reversing the drug and raising clot risk. Monitor the international normalized ratio (a standardized clotting-time measure) before and 24 hours after each session.

  • Direct oral anticoagulants and antiplatelets — blood thinners (apixaban, rivaroxaban, clopidogrel): Caution. Post-exchange fibrinogen depletion compounds the drug effect, raising bleeding risk. Separate dosing from exchange sessions and defer elective procedures until fibrinogen recovers, typically 24 to 48 hours.

  • ACE inhibitors — angiotensin-converting enzyme inhibitors, blood-pressure drugs (lisinopril, ramipril): Absolute contraindication within 24 hours of albumin-based apheresis. Bradykinin (a vessel-dilating peptide) generated in the circuit is not broken down, causing flushing, severe blood-pressure drops and abdominal cramping.

  • Drugs that ride on plasma proteins and stay in the bloodstream (levothyroxine, phenytoin, valproate, ceftriaxone): Monitor. Plasma exchange removes a substantial fraction, causing under-dosing. Administer immediately after, not before, a session, and check drug levels where assays exist.

  • Therapeutic monoclonal antibodies — laboratory-made antibody drugs (lecanemab, rituximab, adalimumab): Caution. Plasma exchange clears circulating antibody and blunts efficacy. Schedule exchange at least one dosing interval before the next administration, and never in the days following an infusion.

  • Over-the-counter analgesics (aspirin, ibuprofen, naproxen): Caution. Antiplatelet and stomach-irritant effects add to the transient clotting impairment after exchange. Pause for 48 hours around sessions where feasible, or substitute acetaminophen.

  • Supplements with antiplatelet or anticoagulant activity (fish oil, vitamin E, ginkgo, garlic, nattokinase, curcumin): Caution, additive bleeding risk with post-exchange fibrinogen and platelet reduction. Discontinue 7 days before an exchange series and resume once counts normalize.

  • Intravenous immunoglobulin: Monitor. Given together with exchange, the combination outperformed exchange alone (Fuentealba et al., 2025), but it also compounds thrombotic, renal and headache risks. Sequence rather than co-infuse, and hydrate adequately.

  • Live vaccines and recent immunization: Caution. Donor antibodies neutralize live vaccine virus and exchange strips vaccine-induced antibodies. Separate vaccination from plasma procedures by at least three months in either direction.

  • Populations who should avoid Young Plasma Transfusion:

    • Selective immunoglobulin A deficiency (serum immunoglobulin A below 7 mg/dL) or documented anti-immunoglobulin A antibodies
    • New York Heart Association Class III–IV heart failure, or ejection fraction (the share of blood the heart pumps out per beat) below 30%
    • Recent myocardial infarction — heart attack (within 90 days) — or unstable angina (chest pain at rest)
    • Chronic kidney disease stage 4 or worse (estimated glomerular filtration rate below 30 mL/min/1.73 m²)
    • Active bleeding, fibrinogen below 1.5 g/L, or hereditary clotting-factor deficiency
    • Active infection, sepsis (bloodstream infection with organ dysfunction), or low antibody levels from any cause
    • Pregnancy and lactation, in whom no safety data exist
    • Candidates for organ transplantation, in whom alloimmunization can prolong waiting time
    • Active malignancy or cancer within 5 years, mirroring the exclusion criteria applied in every trial

Risk Mitigation Strategies

  • Screen for immunoglobulin A deficiency before the first exposure: Measure serum immunoglobulin A; a level below 7 mg/dL warrants anti-immunoglobulin A antibody testing. This prevents the anaphylaxis pathway responsible for the most severe plasma reactions.

  • Specify male-only or never-pregnant donor plasma: Requesting plasma from male donors reduces transfusion-related acute lung injury by roughly 0.74 cases per 100,000 units by avoiding pregnancy-induced anti-leukocyte antibodies (Saadah et al., 2017).

  • Use pathogen-reduced plasma: Amotosalen, methylene blue or solvent-detergent treatment inactivates enveloped viruses and bacteria, cutting residual transmission risk and, for methylene blue, lowering febrile reactions by about 15 per 100,000 units (Saadah et al., 2017).

  • Cap infusion volume and rate: Limit to one unit (roughly 250 mL) per session at 2–4 mL/kg/hour in adults over 65, the regimen used in controlled trials, to prevent transfusion-associated circulatory overload.

  • Prefer peripheral over central venous access: Peripheral access halved procedure-related adverse events (13.1% versus 20.1%) in the largest exchange program (Boada et al., 2023), avoiding catheter-related collapsed lung, clots and bloodstream infection.

  • Give preventive calcium during apheresis: Oral calcium carbonate 1 g before and intravenous calcium gluconate during the procedure offset citrate binding, preventing the tingling, muscle spasm and irregular heartbeat of hypocalcemia.

  • Space sessions to allow immunoglobulin and fibrinogen recovery: Allow at least 2 weeks between full-volume exchanges and check fibrinogen and immunoglobulin G before each, preventing cumulative antibody depletion and bleeding risk.

  • Observe for 4 hours after each infusion: Transfusion-related acute lung injury and circulatory overload both present within 6 hours; on-site monitoring of oxygen saturation, blood pressure and respiratory rate enables prompt treatment.

  • Insist on an active investigational new drug application: The FDA states that plasma given for non-licensed indications should be administered by a sponsor holding one, which provides adverse-event reporting and independent oversight that a cash-pay clinic lacks.

Therapeutic Protocol

  • Whole young plasma infusion (the original approach): Four to eight units of fresh frozen plasma from donors aged 18–30, one unit weekly. Popularized commercially by Jesse Karmazin’s Ambrosia clinic and used in the Stanford Alzheimer’s trial.

  • Therapeutic plasma exchange with albumin (the removal approach): Weekly full-volume exchange for 6 weeks, then monthly low-volume exchange. Developed by Mercè Boada’s group at Ace Alzheimer Center Barcelona with Grifols, and applied to healthy aging by Dobri Kiprov.

  • Plasma protein fractions (the isolated approach): Daily 100–250 mL infusions over 5 consecutive days, repeated after a treatment-free interval. Developed by Alkahest, founded on Tony Wyss-Coray’s Stanford work; avoids whole-plasma volume load.

  • No approach is presented as the default: No comparative trial has tested young plasma infusion against exchange or against fractions. Practitioners choose on mechanistic belief, not on head-to-head outcome data.

  • Time of day: Morning administration is standard, so that delayed reactions occurring within the six-hour window fall during waking hours when symptoms are noticed and clinic staff are available.

  • Half-life of the compound: Infused albumin persists about 19 days and immunoglobulin G about 21 days, but most candidate signaling proteins clear within hours to days, which is why protocols repeat rather than rely on accumulation.

  • Single versus split dosing: Splitting is standard. Trials used one unit weekly or 250 mL daily across 5 days rather than a single large volume, chiefly to limit circulatory overload rather than for drug-handling reasons.

  • Genetic polymorphisms: No gene-guided dosing exists. APOE ε4 status, MTHFR (a folate-metabolizing enzyme gene) and COMT (a catecholamine-degrading enzyme gene) have not been used to stratify dose in any trial of this intervention.

  • Sex-based differences: No trial has adjusted dose or schedule by recipient sex. Donor sex is selected for safety, not efficacy; the Alzheimer’s plasma trial used male donors exclusively (Sha et al., 2019).

  • Age-related considerations: Trials enrolled up to age 90 but reduced volume and slowed infusion rate in the oldest participants. Above 75, cardiac and renal reserve, not target engagement, governs the ceiling on volume.

  • Baseline biomarker levels: Poorer baseline health, indexed by monocyte and platelet profiles, predicted stronger response in the exchange trial (Fuentealba et al., 2025). Baseline fibrinogen, immunoglobulin G and albumin set the safe number of exchange cycles.

  • Pre-existing health conditions: Heart failure and chronic kidney disease force lower volumes and slower rates. Neurodegenerative disease was the setting for most protocols, so schedules were designed around cognitive endpoints, not healthy-adult use.

Discontinuation & Cycling

  • Not designed as a lifelong therapy: Every protocol is a finite course, typically 4 to 8 sessions over 4 to 24 weeks. No trial has run continuous administration for more than 14 months, so open-ended use is untested.

  • No withdrawal syndrome: Stopping produces no rebound or dependence. Infused proteins simply clear on their normal schedule, and no trial has reported symptoms attributable to discontinuation.

  • No tapering required: Because there is no receptor adaptation or physiologic dependence, courses stop abruptly. The only exception is anticoagulant and immunosuppressant dosing, which may need readjustment once plasma-exchange removal ceases.

  • Effects appear to fade rather than persist: In the exchange trial, the biological-age benefit measured at two months was absent at the later timepoint despite continued treatment (Fuentealba et al., 2025), suggesting compensatory adaptation rather than durable change.

  • Cycling is the de facto pattern, not a validated strategy: Practitioners space courses months apart, but no study has compared cycling schedules, and the apparent loss of effect with repeated sessions argues against assuming more is better.

Sourcing and Quality

  • Licensed collection establishments only: Plasma must come from an establishment registered with the FDA or an equivalent national regulator, with donor screening, infectious-disease testing and traceability. Unregistered supply routes carry unquantifiable infection risk.

  • AABB accreditation of the collecting facility: AABB is the professional association whose members are blood banks and transfusion services that derive revenue from the products its standards govern; its accreditation nonetheless remains the practical marker of collection quality.

  • Pathogen-reduction technology: Prefer amotosalen-treated, methylene-blue-treated or solvent-detergent-treated plasma. Each inactivates enveloped viruses and bacteria; solvent-detergent pooling additionally dilutes donor-specific antibodies that drive lung injury.

  • Donor age and sex specification: Protocols claiming a young-donor effect should document a donor age ceiling, typically 30 years, and male-only or never-pregnant sourcing. Clinics unable to document donor age are not delivering the studied intervention.

  • ABO and Rh compatibility documentation: Plasma must be ABO-compatible in the reverse direction from red cells. Written confirmation of compatibility testing for every unit prevents red-cell destruction by donor blood-group antibodies.

  • Cold chain and thaw records: Fresh frozen plasma is stored at −18 °C or below and used within 24 hours of thawing at 30–37 °C. Absent thaw-time documentation, coagulation-factor content and sterility are unverifiable.

  • Compounding pharmacies are not a source: Plasma is a licensed biologic collected under blood-establishment rules, not a compoundable preparation. Any facility offering compounded “plasma factors” is outside the regulatory framework entirely.

Practical Considerations

  • Time to effect: Protein and immune-signaling changes appear within days of infusion. Clock-based changes were measurable at one to two months and had faded by five months (Fuentealba et al., 2025), so any window of effect appears narrow.

  • Common pitfall — treating surrogate markers as outcomes: Epigenetic clock scores, proteomic signatures and biomarker panels are the endpoints in nearly every study. None has been validated as a stand-in for morbidity or mortality after an intervention.

  • Common pitfall — conflating the two procedures: Young plasma infusion adds donor plasma; therapeutic plasma exchange removes the recipient’s. Clinics market them interchangeably, but the strongest human data come from exchange, which contains no young plasma.

  • Common pitfall — skipping the pre-infusion workup: Immunoglobulin A level, fibrinogen, ABO typing and cardiac assessment are routine in trials and frequently omitted in commercial settings, converting a screenable hazard into an unscreened one.

  • Regulatory status: Plasma is licensed only for bleeding, coagulation-factor deficiency and specific exchange indications. Use for aging is not FDA-approved; the agency issued a formal warning in 2019 and states such use requires an investigational new drug application.

  • Cost and accessibility: Exceptionally expensive and entirely out-of-pocket. Commercial infusions have been priced at roughly $8,000 per two-liter course, and exchange programs run $3,000–$12,000 per series, with no insurance coverage for non-licensed indications.

  • Payer incentives and structural bias: Insurers and national health systems reimburse plasma exchange for approved neurological and blood disorders but not for aging, giving payers a systematic incentive against expansion while plasma manufacturers have the opposite incentive; both shape which trials get funded.

Interaction with Foundational Habits

  • Sleep: Indirect and bidirectional. No trial has measured sleep after plasma administration. Cerebrospinal fluid factors implicated in the same rejuvenation pathways are themselves regulated by sleep, meaning poor sleep plausibly erodes the substrate the intervention aims to supply. Schedule morning sessions so post-infusion monitoring does not displace sleep.

  • Nutrition: Indirect. Adequate protein intake maintains serum albumin and immunoglobulin reserve, which determines how many exchange cycles are tolerable before depletion. There are no foods to avoid, but low-protein or low-calorie dieting during an exchange series compounds the transient fall in total protein and fibrinogen.

  • Exercise: Potentiating and partly redundant. Exercise raises several of the same circulating factors that young plasma is thought to supply, which is the rationale for the ExPlas trial transfusing plasma from fit donors (NCT05068830). Avoid vigorous exercise for 24 hours after exchange while fibrinogen and platelets recover.

  • Stress management: Indirect. Cortisol and inflammatory signaling shape the plasma proteome the intervention seeks to alter, and baseline inflammatory status predicted who responded in the exchange trial (Fuentealba et al., 2025). Chronic stress plausibly moves the recipient toward the high-inflammation profile that responded best, but no study has tested this.

Monitoring Protocol & Defining Success

Before a first exposure, establish a baseline that both enables safe administration and provides a comparator for any claimed effect. Essential pre-treatment work comprises ABO and Rh typing with an antibody screen, serum immunoglobulin A to exclude deficiency, a complete blood count, fibrinogen, a comprehensive metabolic panel including albumin and creatinine, and baseline viral serology so that any later infection can be correctly attributed. Where plasma exchange is used, add ionized calcium and immunoglobulin G. Ongoing monitoring is tied to the procedure schedule rather than to a calendar: check fibrinogen, immunoglobulin G and calcium immediately before every full-volume exchange, repeat the metabolic panel and blood count at 4 weeks, then at 3 months and every 6 months thereafter. Repeat viral serology at 3 and 6 months after the final exposure.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum immunoglobulin A Above 70 mg/dL Identifies deficiency that drives anaphylaxis Single pre-treatment test; below 7 mg/dL requires anti-immunoglobulin A antibody testing. Conventional labs flag only values under 70 mg/dL as abnormal
Immunoglobulin G 800–1,400 mg/dL Detects cumulative antibody depletion from exchange Draw before each exchange, not after. Values persisted near 7.2 g/L between sessions in trial patients (Grifols et al., 2023), at the bottom of the 7.0–16.0 g/L conventional range
Fibrinogen 200–350 mg/dL Predicts post-exchange bleeding risk Below 150 mg/dL, defer the session. Conventional range extends to 400 mg/dL, but values above 350 mg/dL indicate inflammation
Ionized calcium 1.15–1.30 mmol/L Detects citrate-induced hypocalcemia during apheresis Measure mid-procedure, not just before. Total calcium underestimates the deficit when albumin is replaced
Serum albumin 4.2–5.0 g/dL Reflects protein reserve and volume tolerance Fasting sample preferred. Conventional range starts at 3.5 g/dL, which functional practitioners regard as already depleted
High-sensitivity C-reactive protein Below 0.5 mg/L Baseline inflammation predicted stronger response Defer testing for 2 weeks after infection or vaccination. Conventional cardiovascular cut-off is 3.0 mg/L, far above the functional target
Interleukin-6 Below 1.5 pg/mL Tracks the inflammatory signaling the intervention targets Morning draw; levels follow a diurnal rhythm. Pair with high-sensitivity C-reactive protein
Estimated glomerular filtration rate Above 90 mL/min/1.73 m² Determines tolerance of infused volume Cystatin C-based estimate preferred in low-muscle-mass individuals. Below 30 is a contraindication
Complete blood count with platelets Platelets above 200 ×10⁹/L; hemoglobin 13.5–15.0 g/dL (men), 12.5–14.0 g/dL (women) Monitors procedural depletion and monocyte profile Platelets and monocytes predicted responsiveness in the exchange trial (Fuentealba et al., 2025). Draw before each series
Epigenetic age (DNA methylation clock) No established target exists; track change from the individual’s own baseline The endpoint on which benefit claims rest Use the same laboratory and clock each time; between-assay variation exceeds the reported effect size. Not a validated clinical outcome
Viral serology (HIV, hepatitis B, hepatitis C) Negative Establishes pre-exposure status for attribution Baseline, then 3 and 6 months after final exposure. Nucleic acid testing shortens the detection window

Qualitative markers worth tracking alongside laboratory values, using a fixed weekly self-rating rather than recall:

  • Energy and daily stamina, rated at the same hour each day
  • Cognitive clarity, word-finding and processing speed
  • Sleep quality and time to fall asleep
  • Exercise capacity and recovery time after a standardized session
  • Mood stability and motivation
  • Any infusion-day symptoms: chills, flushing, tingling, breathlessness

Emerging Research

Research directions below are framed for someone weighing whether to act now or wait, and include work that could strengthen and work that could weaken the case.

  • Plasma from exercise-trained donors in early Alzheimer’s disease: The ExPlas trial (NCT05068830) is transfusing plasma from fit male donors aged 18–40 into 60 patients, with safety as the primary endpoint and cognition, cerebral blood flow and hippocampal volume as secondary measures (Tari et al., 2022).

  • Longer-term plasma exchange schedules in healthy older adults: The trial behind the biological-age report (NCT06534450) compared biweekly and monthly regimens in 40 adults over 50. Whether repeated cycles sustain or blunt the effect is the central unanswered question (Fuentealba et al., 2025).

  • Umbilical cord plasma for age-related cognitive decline: A phase 1 study (NCT04566757) sponsored by the American Academy of Regenerative Medicine, a professional body whose members offer such infusions commercially, planned 12 participants. Its registry status has not been updated since 2021.

  • Young-donor plasma for frailty and immune decline: A phase 1/2 study (NCT03458429) is giving 30 frail adults aged 55–95 twelve monthly transfusions of fresh frozen plasma from donors aged 18–35, with safety primary and immune risk profile, cognition and frailty index as secondary measures.

  • Evidence that could weaken the case — donor age in large registries: A Canadian cohort found higher recipient mortality with younger donors (Chassé et al., 2016), while a Scandinavian analysis of 968,264 recipients found the association vanished after correcting for transfusion number (Edgren et al., 2017).

  • Evidence that could weaken the case — dilution rather than youthful factors: If removing old plasma alone reproduces the benefit (Mehdipour et al., 2020), then paying a premium for young-donor plasma buys nothing beyond what albumin exchange delivers, and the donor-age premium collapses.

  • Isolated factors instead of whole plasma: Work on TIMP2 from cord plasma (Castellano et al., 2017) and on GDF11 points toward defined recombinant proteins. If successful, this would replace transfusion entirely and eliminate its infectious, allergic and volume risks.

  • Lifespan endpoints in animals: Young plasma extended mean lifespan and shifted methylation profiles in old rats (Chiavellini et al., 2024). No human survival study is registered, and none is likely given the required duration and sample size.

Conclusion

Young plasma transfusion takes a laboratory finding of real substance — that old animals sharing a young animal’s circulation recover tissue repair and memory — and applies it to people, where the supporting evidence is far thinner than the marketing implies. The human trials are small, mostly in people with dementia or Parkinson’s disease rather than healthy adults, and almost all of them measured laboratory markers rather than how anyone actually felt or functioned.

Two findings deserve weight. Plasma exchange, which removes a person’s own plasma rather than adding a young donor’s, produced the clearest signals, and one careful trial of removal alone pointed the opposite way. That pattern suggests the active ingredient, if there is one, may be what is taken out rather than what is put in — which would make donor age irrelevant.

The harms, by contrast, are well characterized, because transfusing plasma is an old procedure with decades of tracked reactions: allergic responses, lung injury, fluid overload, and the slow stripping of antibodies and clotting proteins with repeated exchange.

Much of the supporting work comes from companies that sell plasma, the equipment to exchange it, or the clinics that administer it, and the professional bodies whose standards govern it are made up of members who profit from its use. For someone weighing an expensive, invasive, uninsured procedure, that context is part of the evidence.

Top - Benefits - Risks - Protocol